Dr. Amir Fathi

0:02:53

Dr. Amir Fathi Interprets the Latest Developments in Targeted Therapy for Acute Myeloid Leukemia

0:04:23

Dr. Fathi Helps Retired Officer Reclaim Life After Surgery to Overcome Infection

0:06:16

Adding Menin Inhibitors in Combination Therapy for AML Patients | Amir Fathi, MD | #ASH24

0:01:33

IDH Inhibition in Acute Myeloid Leukemia –Emergence of a New Therapeutic Era

0:04:23

How would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?

0:01:13

A Phase I trial combining PF-08046040 (SEA-CD70) with azacitidine to treat MDS

0:05:34

SGN-CD33A Plus Hypomethylating in frontline Unfit AML patients

0:02:16

Developing targeted therapies to address heterogeneity in AML

0:03:33

Amir Fathi | Alisertib in combination with induction chemotherapy in high-risk patients with AML

0:00:51

Unmet needs in front-line therapy for patients with FLT3-mutated AML

0:01:35

AML in 2022 and beyond

0:05:12

How could new immunotherapy treatments in acute myeloid leukemia change current practice?

0:10:21

Dr Amir Fathi (Abstract S503):

0:01:29

Factors that prevent the personalization of therapies in AML

0:01:53

Treatment strategies for patients with IDH1/2-mutated AML ineligible for intensive chemotherapy

0:03:20

Differentiation syndrome with lower-intensity therapy for AML

0:03:17

Ziftomenib: mechanism of action and promising results in patients with KMT2Ar or NPM1m AML

0:03:35

With Rare Condition, Patient Survives on Liquid Diet for over a year

0:02:50

IDH inhibition in AML therapy

0:05:07

How could new immunotherapy modalities in AML change current practice?

0:02:18

Early findings of a Phase I study of KO-539 in patients with R/R AML

0:01:41

The emerging role of menin inhibitors in the treatment of NPM1-mutated and KMT2A-rearranged R/R AML

0:03:12

Asst. Prof. Fathi | Differentiation syndrome associated with enasidenib (AG-221, an IDH2i)

0:02:18

The KOMET-007 trial: investigating combinations with ziftomenib in newly diagnosed and R/R AML